Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.

Business area of the company

The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.

Dr. Reddy's Laboratories Ltd.

Divi's Laboratories Ltd.

Cipla Ltd.

Torrent Pharmaceuticals Ltd.

Abbott India Ltd.

Zydus Lifesciences Ltd.

Alkem Laboratories Ltd.

Lupin Ltd.

Biocon Ltd.

Gland Pharma Ltd.

Aurobindo Pharma Ltd.

Laurus Labs Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Ipca Laboratories Ltd.

Piramal Enterprises Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	72,827 Cr		EPS	142.7		High	4383
Stock P/E	30.6		Net Profit Margin	17.4		Low	4320

Market Cap	72,827 Cr	ROE	26.6%
P/E Ratio(TTM)	30.6	EPS(TTM)	179.6
P/B Ratio	3.8	Dividend Yield	0.7%
Industry P/E	65.2	Book Value	1.2K
		Face Value	5.0

DRREDDY